Sun Pharmaceutical Industries Stock Fundamentals
| SUNPHARMA | 1,799 3.60 0.20% |
Sun Pharmaceutical Industries fundamentals help investors to digest information that contributes to Sun Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Sun Stock. The fundamental analysis module provides a way to measure Sun Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sun Pharmaceutical stock.
At this time, Sun Pharmaceutical's Income Before Tax is relatively stable compared to the past year. As of 11/26/2024, Net Income is likely to grow to about 100.6 B, while Gross Profit is likely to drop slightly above 142.5 B. Sun | Select Account or Indicator |
Sun Pharmaceutical Industries Company Return On Equity Analysis
Sun Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sun Pharmaceutical Return On Equity | 0.17 |
Most of Sun Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sun Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Sun Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Sun Pharmaceutical Industries has a Return On Equity of 0.1677. This is 100.7% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all India stocks is 154.1% lower than that of the firm.
Sun Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sun Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Sun Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sun Pharmaceutical competition to find correlations between indicators driving Sun Pharmaceutical's intrinsic value. More Info.Sun Pharmaceutical Industries is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.51 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sun Pharmaceutical Industries is roughly 1.96 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sun Pharmaceutical's earnings, one of the primary drivers of an investment's value.Sun Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sun Pharmaceutical's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sun Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sun Pharmaceutical by comparing valuation metrics of similar companies.Sun Pharmaceutical is currently under evaluation in return on equity category among its peers.
Sun Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sun Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sun Pharmaceutical's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Sun Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0854 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 4.13 T | ||||
| Shares Outstanding | 2.4 B | ||||
| Shares Owned By Insiders | 55.10 % | ||||
| Shares Owned By Institutions | 26.30 % | ||||
| Price To Book | 6.23 X | ||||
| Price To Sales | 8.61 X | ||||
| Revenue | 484.97 B | ||||
| Gross Profit | 332.24 B | ||||
| EBITDA | 138.36 B | ||||
| Net Income | 95.76 B | ||||
| Cash And Equivalents | 13.87 B | ||||
| Total Debt | 32.74 B | ||||
| Book Value Per Share | 288.72 X | ||||
| Cash Flow From Operations | 121.35 B | ||||
| Earnings Per Share | 46.14 X | ||||
| Target Price | 2043.32 | ||||
| Number Of Employees | 43 K | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 4.31 T | ||||
| Total Asset | 854.63 B | ||||
| Retained Earnings | 501.59 B | ||||
| Working Capital | 264.91 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 854.63 B |
About Sun Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sun Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sun Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sun Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.3 B | 1.2 B | |
| Total Revenue | 485 B | 509.2 B | |
| Cost Of Revenue | 226.5 B | 237.8 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sun Stock Analysis
When running Sun Pharmaceutical's price analysis, check to measure Sun Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sun Pharmaceutical is operating at the current time. Most of Sun Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sun Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sun Pharmaceutical's price. Additionally, you may evaluate how the addition of Sun Pharmaceutical to your portfolios can decrease your overall portfolio volatility.